ACA Pharma
ACA Pharma is a US-headquartered, privately held specialty pharmaceutical distributor (founded 1997) that holds exclusive Asia-Pacific distribution rights for branded orphan, rare-disease, and specialty drugs, commercializing them through a 90+ hospital network in China and lighthouse centers in Macau and Singapore.
- Company typePrivate
- Founded1997
- HeadquartersNew York, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What ACA Pharma does
ACA Pharma is a New York-headquartered, privately held specialty pharmaceutical distribution company founded in 1997 that operates as an end-to-end commercialization partner for global pharma manufacturers seeking access to Greater China and Southeast Asia. The company acquires exclusive rights to register and distribute branded, clinically urgent, orphan, and rare-disease drugs, and reaches patients through a curated hospital network anchored by the China NPP Group Procurement program covering 90+ hospitals and approximately 95% of pediatric rare-disease patients in China, plus lighthouse launch centers in Macau and Singapore. Its current portfolio includes Omisirge (FDA-approved cell therapy from Ayrmid Ltd., for hematologic malignancies), RYANODEX and Barhemsys (from Eagle Pharmaceuticals, for malignant hyperthermia and related indications), and Feraheme (from Azurity Pharmaceuticals, for iron-deficiency anemia), with RYANODEX territory expanded in late 2025 into Europe, Latin America, the Middle East, and broader Asia-Pacific.
ACA Pharma monetizes through product-distribution margins on exclusive territory licenses from manufacturer partners and through its role as gatekeeper of prioritized hospital procurement for rare and clinically urgent drugs in Asia-Pacific. Its go-to-market relies on clinician education, professional society partnerships (e.g., the Indian Society of Anaesthesiologists for the Ryanodex India launch), and regulatory navigation — including sequencing launches through fast-track jurisdictions before broader rollout. Pricing is not publicly disclosed; transaction economics are negotiated through hospital procurement programs and country-level regulatory approvals rather than standardized list pricing. Geographic coverage spans at least 15 markets (Mainland China, Hong Kong SAR, Macau SAR, Mongolia, Brunei, Cambodia, Indonesia, Lao PDR, Malaysia, Myanmar, Philippines, Singapore, Thailand, Vietnam, Timor-Leste), with offices in Hong Kong, Macau, Singapore, and Mainland China, and recent extensions into India, Europe, LATAM, and the Middle East.
ACA Pharma firmographics
Firmographics- Name
- ACA Pharma
- Website
- https://acapharma.net
- Company type
- Private
- Founded year
- 1997
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- ACA Pharma is a US-headquartered, privately held specialty pharmaceutical distributor (founded 1997) that holds exclusive Asia-Pacific distribution rights for branded orphan, rare-disease, and specialty drugs, commercializing them through a 90+ hospital network in China and lighthouse centers in Macau and Singapore.
- Ownership category
- akta.pro rank
ACA Pharma industry classification
Industry- Product category
- Specialty Pharmaceutical Distribution
- NAICS
- Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Specialty Pharmaceutical Distributors (HLAIAJAB)
- akta.pro secondary industries
- Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD), Specialty Pharmacies (Complex/High-Cost Therapies) (HLAFALAC), Specialty Care Pharmaceuticals (HLAIAAAB)
Keywords
Where ACA Pharma is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
ACA Pharma business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Supply Chain, Operations, Personnel, Marketing or Sales
Revenue model
- Pharmaceutical Distribution: ACA Pharma generates revenue as an exclusive distributor of specialty pharmaceutical products across Asia-Pacific markets. The company acquires exclusive rights to register and distribute innovative drugs, earning margins on product sales through hospital networks and pharmacy channels.
- Exclusive Licensing Agreements: Revenue derived from exclusive distribution partnerships with global pharmaceutical companies (Eagle Pharmaceuticals, Azurity Pharmaceuticals, Ayrmid Ltd.) for branded specialty medications in defined territories.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels3 records
ACA Pharma product offering
Product offeringCore offering
ACA Pharma operates as an exclusive specialty pharmaceutical distributor that acquires distribution rights from global pharma manufacturers for innovative drugs (orphan drugs, cell therapies, rare-disease treatments) and commercializes them across Asia-Pacific markets. The company leverages fast-track regulatory registration routes, established hospital networks (90+ hospitals in China via the NPP Group Procurement program), and clinician education programs to deliver specialty pharmaceutical products to healthcare providers and patients in 15 markets across Greater China and Southeast Asia.
Product overview
ACA Pharma operates as a specialty pharmaceutical distribution company with a portfolio of FDA-approved and clinically urgent drugs. The company functions as exclusive distributor for multiple pharmaceutical products across Asia-Pacific markets, including: Omisirge (cell therapy for hematologic malignancies), RYANODEX (for malignant hyperthermia), Barhemsys (specialty pharmaceutical), and Feraheme (iron replacement therapy). The company also manages the China NPP Group Procurement Program providing prioritized hospital access for orphan and rare-disease drugs. The product portfolio is distributed through exclusive manufacturer partnerships with companies including Ayrmid Ltd., Eagle Pharmaceuticals, and Azurity Pharmaceuticals.
Differentiator
Problem solved
Functional benefit
Products and services
- Omisirge FDA-approved cell therapy (Omidubicel-onlv) for hematologic malignancies and severe aplastic anemia, distributed exclusively by ACA Pharma across 15 markets in Greater China and Southeast Asia for healthcare providers treating patients with hematologic malignancies.
- RYANODEX Drug developed by Eagle Pharmaceuticals for malignant hyperthermia emergency treatment, distributed exclusively by ACA Pharma across Hong Kong, Macau, Singapore, Greater China, and expanded territories in Europe, Latin America, Middle East, and Asia-Pacific.
- Barhemsys Specialty pharmaceutical product distributed by ACA Pharma under exclusive distribution agreement with Eagle Pharmaceuticals across Hong Kong, Macau, Singapore, and Greater China for healthcare providers.
- Feraheme Intravenous iron replacement therapy for iron deficiency anemia, distributed exclusively by ACA Pharma in Hong Kong, Macau, Greater Bay Area, Mainland China, and Singapore under partnership with Azurity Pharmaceuticals.
- China NPP Group Procurement Program Prioritized access program for orphan, pediatric rare-disease, and clinically urgent drugs operated through a network of over 90 hospitals in China covering approximately 95% of pediatric rare disease patients.
Quantifiable outcome
- 95% coverage of pediatric rare disease patients in China through NPP Group Procurement network
- +2 more outcomes
Companies that use ACA Pharma
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles2 records
ACA Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
ACA Pharma partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- Ayrmid Ltd. (parent of Gamida Cell Inc.)coreACA Pharma appointed as exclusive distributor for Omisirge (FDA-approved cell therapy) across 15 markets in Greater China and Southeast Asia, covering Mainland China, Hong Kong SAR, Macau SAR, Mongolia, Brunei, Cambodia, Indonesia, Lao PDR, Malaysia, Myanmar, Philippines, Singapore, Thailand, Vietnam, and Timor-Leste. ACA Pharma holds exclusive rights to register and distribute the therapy, with initial lighthouse centers planned in Macau and Singapore before expanding to additional jurisdictions.
- Indian Society of AnaesthesiologistsminorProfessional medical society partnership hosting virtual nationwide launch of Ryanodex in India to improve emergency response to malignant hyperthermia. Eagle Pharmaceuticals (manufacturer) and ACA Pharma (distribution partner) collaborated with the society for this launch event.
- Azurity PharmaceuticalscoreACA Pharma and Azurity Pharmaceuticals announced exclusive distribution partnership for Feraheme (intravenous iron replacement therapy) in Hong Kong, Macau, Greater Bay Area, Mainland China, and Singapore. Feraheme is used for iron deficiency anemia, which is widespread in the region.
- Eagle PharmaceuticalscoreACA Pharma signed exclusive distribution agreement with Eagle Pharmaceuticals to commercialize Ryanodex and Barhemsys across Hong Kong, Macau, Singapore, and Greater China. Products have completed or are progressing in regulatory approval processes, with plans for expansion into Latin America, Europe, and other areas. Also expanded territory for RYANODEX distribution across Europe, Latin America, Middle East, and Asia-Pacific.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
ACA Pharma competitors and assessment
Company assessmentBroad incumbents
- McKesson: One of the largest pharmaceutical distributors globally with operations in North America and Europe. Comparable at the level of specialty pharmaceutical distribution infrastructure, but operates as a broad incumbent rather than a focused Asia-Pacific commercialization partner.
- DHL Supply Chain (Life Sciences & Healthcare): Global logistics provider with a dedicated Life Sciences & Healthcare division offering GDP-compliant pharma distribution, cold chain, and clinical trial logistics. Overlapping capability with ACA Pharma's specialty pharma and biologics distribution, though DHL operates as a broader portfolio logistics player rather than a focused commercial distributor.
- Cardinal Health: Major U.S.-based pharmaceutical distributor with global reach including specialty distribution capabilities. Broad incumbent peer for ACA Pharma's specialty pharma distribution model, though Cardinal Health primarily serves U.S. and select international markets rather than Asia-Pacific-focused distribution.
- Cencora (AmerisourceBergen): Top-tier global pharmaceutical distributor with significant specialty pharma, animal health, and global commercialization services (through PharmaLex and World Courier). Comparable in serving specialty and orphan drug manufacturers with distribution and market access services, though at much greater scale and global reach than ACA Pharma.
Direct peers
- DKSH Holding: Swiss-listed market expansion services company that helps pharmaceutical, consumer, and specialty product companies grow in Asia. Directly comparable as an Asia-focused commercialization and distribution partner with similar exclusive-agreement-driven business model for healthcare clients.
- World Courier (Cencora): Specialty logistics and distribution arm of Cencora focused on cell and gene therapies, orphan drugs, and time/temperature-sensitive pharmaceuticals. Highly comparable to ACA Pharma's specialty distribution focus on cell therapies (Omisirge) and rare disease drugs across multiple jurisdictions.
- Mega Lifesciences: Thailand-headquartered pharma distribution and marketing company focused on emerging Asia-Pacific markets. Comparable in serving as a regional commercialization partner for international specialty and branded pharmaceutical manufacturers.
- Zuellig Pharma: One of the largest healthcare distribution companies in Asia-Pacific, providing pharma distribution, market access, and patient-centric services across 16+ markets. Closest comparable to ACA Pharma in business model (specialty pharma distribution for innovator manufacturers) and geographic footprint (Greater China and Southeast Asia).
Regional players
- Shanghai Pharmaceuticals Holding: One of China's largest pharmaceutical distribution and manufacturing groups, listed in Hong Kong and Shanghai. Regional comparable for ACA Pharma's China-centric hospital distribution and procurement programs, though it operates as a domestic incumbent at much larger scale.
Emerging players
- TransAsian Pharma / Bharat Serums and Vaccines (Asia arm): Specialty pharmaceutical companies expanding distribution partnerships for branded and complex-therapy products across Asia. Comparable as smaller specialty distributors leveraging exclusive partnerships to commercialize innovator products in emerging Asian markets.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
ACA Pharma social profiles
Digital presenceACA Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
ACA Pharma leadership team
Management profileNumber of profiles
ACA Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ACA Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ACA Pharma
What does ACA Pharma do?
ACA Pharma operates as an exclusive specialty pharmaceutical distributor that acquires distribution rights from global pharma manufacturers for innovative drugs (orphan drugs, cell therapies, rare-disease treatments) and commercializes them across Asia-Pacific markets. The company leverages fast-track regulatory registration routes, established hospital networks (90+ hospitals in China via the NPP Group Procurement program), and clinician education programs to deliver specialty pharmaceutical products to healthcare providers and patients in 15 markets across Greater China and Southeast Asia.
Is ACA Pharma a public or private company?
ACA Pharma is a private company. It is classified as unknown and is currently operating.
When was ACA Pharma founded?
ACA Pharma was founded in 1997. It employs 1 to 10 people.
Where is ACA Pharma based?
ACA Pharma is headquartered in New York, United States, in the North America region.
How does ACA Pharma make money?
Two revenue lines are on record. Pharmaceutical Distribution is the primary driver. The others are exclusive Licensing Agreements.
Who are ACA Pharma's main competitors?
Broad incumbents on record are McKesson, DHL Supply Chain (Life Sciences & Healthcare), Cardinal Health and Cencora (AmerisourceBergen). Direct peers are DKSH Holding, World Courier (Cencora), Mega Lifesciences and Zuellig Pharma. Shanghai Pharmaceuticals Holding is listed as a regional player. TransAsian Pharma / Bharat Serums and Vaccines (Asia arm) is listed as an emerging player.
Does ACA Pharma have an API?
No public API is recorded for ACA Pharma.
What industry is ACA Pharma in?
ACA Pharma's product category is Specialty Pharmaceutical Distribution. Its primary akta.pro industry code is HLAIAJAB, Specialty Pharmaceutical Distributors, with a secondary code of HLAGAMAD, Specialty Pharma & Biologics Distribution (GDP-compliant). Its NAICS code is 424210 and its SIC code is 5122.